Tirzepatide maintenance trial tests a lower dose instead of stopping
A completed tirzepatide trial is the first randomized look at whether stepping down to a lower dose can hold weight loss, but no results are posted yet.
A 112-week phase 3b trial called SURMOUNT-MAINTAIN has finished, testing whether people taking tirzepatide can hold onto their weight loss by moving to a lower dose instead of stopping the drug. At week 60, 378 of the 441 enrolled participants were randomized to one of three paths: continue their maximum tolerated dose, step down to 5 mg, or switch to placebo [1].
The study is registered as NCT06047548, titled "A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities" [1]. LY3298176 is the development code for tirzepatide [1]. The trial ran at 20 US sites [1].
The design is unusual in one respect. In most weight-loss drug trials, everyone who responds to treatment keeps taking it, and the comparison is drug against placebo. SURMOUNT-MAINTAIN instead randomizes people after a 60-week run-in, so only those who reached that point continued into the comparison phase — 378 of 441 people enrolled, meaning 63 did not [1]. Participants were then assigned either the full maximum tolerated dose, a 5 mg dose (the lowest approved starting strength for tirzepatide), or a placebo injection [1]. It is described as the first randomized test of dose reduction rather than discontinuation.
What the trial has not produced yet is any outcome data. No weight-change numbers, no rates of weight regain, no information on side effects in any of the three groups, and no count of how many people finished the 112 weeks have been reported [1]. The registry listing does not disclose when results will be posted or whether the findings will be published in a medical journal [1].
Why it matters for patients
Much of what patients hear about stopping a GLP-1 drug comes from trials that compared the drug with a placebo, which leaves out the option many people actually consider: staying on treatment at a lower dose. This trial was built around that middle ground, comparing a step-down to 5 mg against both full-dose continuation and placebo [1].
If the 5 mg arm holds weight reasonably well, it would give doctors a documented option between "stay on the highest dose you tolerate" and "stop," which could matter for people who struggle with side effects at higher doses, for people facing cost or insurance limits, and for anyone hoping to reduce how much drug they need over time.
None of that is settled by this trial finishing. The finish line is the end of data collection, not evidence. Until the results are posted, there is no way to know whether the 5 mg group regained weight, lost the benefit entirely, or did about as well as the full-dose group.
The findings will also apply only to tirzepatide. Whether a similar step-down holds for semaglutide (Ozempic, Wegovy, Rybelsus) or for orforglipron (Foundayo) has not been tested in this trial [1].
What happens next
The trial's status is listed as completed [1]. A date for posting results on ClinicalTrials.gov, or for presenting them at a medical conference, has not been disclosed [1].
What the trial will not answer, at least not on its own: whether a lower maintenance dose changes the risk of side effects, whether it changes cost or insurance coverage, and how a step-down compares with staying on the full dose over periods longer than 112 weeks. Those questions are not addressed in the registry listing [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.